美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

SPDR S&P Biotech ETF

156.20

-0.6200-0.40%

盤後：156.430.2300+0.15%19:59 EDT

成交量：841.39萬

成交額：13.25億

市值：105.24億

市盈率：8.57

高：159.66

開：158.27

低：156.13

收：156.82

52周最高：169.89

52周最低：92.64

股本：6,737.50萬

流通股本：6,737.50萬

量比：1.28

換手率：12.49%

股息：0.56

股息率：0.36%

每股收益(TTM):18.23

淨資產收益率：--

總資產收益率：--

市淨率：--

市盈率(LYR):- -

資料載入中...

總覽公司新聞公告

從8000元降價到200元！福建山區小縣登上人民日報

百餘家上市公司發布2026年半年報生物醫藥等行業現亮點

百餘家上市公司發布2026年半年報生物醫藥等行業現亮點

宜明昂科-B(01541)附屬宜明凱爾生物醫藥技術(上海)獲增資5000萬元

宜明昂科-B(01541.HK)附屬宜明凱爾生物醫藥技術(上海)獲增資5000萬元

醫療保健板塊市場動態綜述

生物科技IPO熱潮持續!心血管藥企Braveheart(BRVE.US)募資擴大至3.825億美元，發行價突破指引上限

醫療板塊市場動態速覽

海關試點跨關區協同監管新模式

东北新闻网

構建社保商保分層協同機制，破解創新藥支付困境——商業醫療保險與創新藥支付管理研討會在京召開

生物科技公司Braveheart在美國IPO中籌集3.825億美元。

上海國投先導、恩華藥業等在上海成立創投基金

醫療保健板塊動態：市場快評

醫療保健板塊快訊：市場動態一覽

高盛支持的生物科技公司Attovia在美國IPO中籌集2.89億美元

醫療保健板塊動態：市場快評

醫療保健板塊動態：市場快評

睿唯盛高管在電話會議上表示，受人工智能相關訂單數量增長的推動，公司正迎來生物科技客户需求改善。

「創新+出海」驅動，A股生物醫藥公司盈利能力提升

醫療健康板塊快訊：市場動態一覽

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎證券香港 | 輕鬆買賣美股港股A股/美債/ETF/Crypto/期權期貨","description":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","keywords":"老虎證券,老虎證券開戶,老虎證券香港,老虎證券投資,老虎證券美股,老虎證券登錄,證券開戶,證券公司開戶,股票開戶,香港證券公司,香港證券,證券公司,美股投資平台,小額投資理財,投資app,投資平台,股票買賣,買賣股票平台,炒股app,證券app,新手投資","social":{"ogDescription":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrcrest.com/hant/stock/XBI/news?page=10"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"XBI","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"XBI\",,,,,undefined,":{"symbol":"XBI","market":"US","secType":"STK","nameCN":"SPDR S&P Biotech ETF","latestPrice":156.2,"timestamp":1789156800000,"preClose":156.82,"halted":0,"volume":8413893,"hourTrading":{"tag":"盘后","latestPrice":156.43,"preClose":156.2,"latestTime":"19:59 EDT","volume":555911,"amount":86836947.7522,"timestamp":1789171191129,"change":0.23,"changeRate":0.001472,"amplitude":0.001601},"delay":0,"changeRate":-0.0039535773498278574,"floatShares":67375000,"shares":67375000,"eps":18.23,"marketStatus":"休市中","change":-0.62,"latestTime":"09-11 16:00:00 EDT","open":158.27,"high":159.6607,"low":156.13,"amount":1324607084.0494199,"amplitude":0.022514,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":18.23,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1789372800000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"ARCA","adjPreClose":156.82,"sharesOutstanding":63325000,"nav":156.174274,"aum":10736981366.38,"dividendRate":0.003615,"bidAskSpread":0.000302,"preHourTrading":{"tag":"盘前","latestPrice":158.23,"preClose":156.82,"latestTime":"09:29 EDT","volume":40501,"amount":6393566.4319400005,"timestamp":1789133399999,"change":1.41,"changeRate":0.008991,"amplitude":0.013009},"postHourTrading":{"tag":"盘后","latestPrice":156.43,"preClose":156.2,"latestTime":"19:59 EDT","volume":555911,"amount":86836947.7522,"timestamp":1789171191129,"change":0.23,"changeRate":0.001472,"amplitude":0.001601},"volumeRatio":1.2777409531718278,"optionData":{"bulkOrders":[{"symbol":"XBI","call":false,"expireDate":1790308800000,"strike":"157.0","timestamp":1789148514638,"price":3.65,"volume":2865,"amount":1045725,"type":"+"},{"symbol":"XBI","call":false,"expireDate":1790308800000,"strike":"150.0","timestamp":1789148514638,"price":1.15,"volume":2865,"amount":329475,"type":"-"}]},"impliedVol":0.2874,"impliedVolPercentile":0.1554},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"XBI\",,,,,undefined,":{"symbol":"XBI","floatShares":67375000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":1.2777409531718278,"shares":67375000,"dividePrice":0.5646,"high":159.6607,"amplitude":0.022514,"preClose":156.82,"low":156.13,"week52Low":92.64,"pbRate":"--","week52High":169.89,"institutionHeld":0.8511,"latestPrice":156.2,"eps":18.23,"divideRate":0.003615,"volume":8413893,"delay":0,"ttmEps":18.23,"open":158.27,"prevYearClose":121.93,"prevWeekClose":163.81,"prevMonthClose":162.5,"prevQuarterClose":158.25,"fiveDayClose":164.38,"twentyDayClose":156.86,"sixtyDayClose":135.34},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/XBI\",params:#limit:5,,,undefined,":[{"date":"2026-06-22","symbol":"XBI","amount":0.138094,"announcedDate":"2026-06-18","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-06-22","defaultRemindTime":1782135000000,"name":"SPDR S&P Biotech ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-06-24","payableDate":"2026-06-22","currency":"USD","dateTimestamp":1782100800000,"payDate":"2026-06-24"},{"date":"2025-12-22","symbol":"XBI","amount":0.406564,"announcedDate":"2025-12-19","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-22","defaultRemindTime":1766413800000,"name":"SPDR S&P Biotech ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-24","payableDate":"2025-12-22","currency":"USD","dateTimestamp":1766379600000,"payDate":"2025-12-24"},{"date":"2025-09-22","symbol":"XBI","amount":0.02665,"announcedDate":"2025-09-19","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-09-22","defaultRemindTime":1758547800000,"name":"SPDR S&P Biotech ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-09-24","payableDate":"2025-09-22","currency":"USD","dateTimestamp":1758513600000,"payDate":"2025-09-24"},{"date":"2025-06-23","symbol":"XBI","amount":0.007295,"announcedDate":"2025-06-20","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-06-23","defaultRemindTime":1750685400000,"name":"SPDR S&P Biotech ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-06-25","payableDate":"2025-06-23","currency":"USD","dateTimestamp":1750651200000,"payDate":"2025-06-25"},{"date":"2025-03-24","symbol":"XBI","amount":0.00525,"announcedDate":"2025-03-21","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-03-24","defaultRemindTime":1742823000000,"name":"SPDR S&P Biotech ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-03-26","payableDate":"2025-03-24","currency":"USD","dateTimestamp":1742788800000,"payDate":"2025-03-26"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"XBI\",market:\"US\",,,undefined,":[{"executeDate":"2016-09-16","recordDate":"2016-09-20","paymentDate":"2016-09-26","value":0.031139,"currency":"USD"},{"executeDate":"2016-12-16","recordDate":"2016-12-20","paymentDate":"2016-12-27","value":0.01831,"currency":"USD"},{"executeDate":"2017-03-17","recordDate":"2017-03-21","paymentDate":"2017-03-27","value":0.019702,"currency":"USD"},{"executeDate":"2017-06-16","recordDate":"2017-06-20","paymentDate":"2017-06-26","value":0.110135,"currency":"USD"},{"executeDate":"2017-09-15","recordDate":"2017-09-18","paymentDate":"2017-09-25","value":0.03704,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"XBI\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"XBI\",pageSize:20,pageCount:10,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2657466712","title":"從8000元降價到200元！福建山區小縣登上人民日報","url":"https://stock-news.laohu8.com/highlight/detail?id=2657466712","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657466712?lang=zh_tw&edition=fundamental","pubTime":"2026-08-07 09:04","pubTimestamp":1786064640,"startTime":"0","endTime":"0","summary":"8月6日，人民日报刊发《延伸链条，老区“长”出新产业》一文，关注福建明溪。“从红豆杉里提取的紫杉醇是抗肿瘤药的有效成分。上世纪末，由于要从树皮里提取，一支制剂能卖到8000元，一公斤原料药值300万元。”随着成本大幅下降，每支紫杉醇制剂价格降到200元。市民在选购进口产品。据了解，明溪县已培育近50家侨资企业，吸引项目投资超20亿元。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2026-08-07/doc-inimmyet0104916.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["XBI","BK4588","BK4585","BK4581"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657360664","title":"百餘家上市公司發布2026年半年報 生物醫藥等行業現亮點","url":"https://stock-news.laohu8.com/highlight/detail?id=2657360664","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657360664?lang=zh_tw&edition=fundamental","pubTime":"2026-08-07 07:36","pubTimestamp":1786059397,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["399441","BK4585","BK4581","161726","BK4588","XBI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657661078","title":"百餘家上市公司發布2026年半年報 生物醫藥等行業現亮點","url":"https://stock-news.laohu8.com/highlight/detail?id=2657661078","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657661078?lang=zh_tw&edition=fundamental","pubTime":"2026-08-07 07:25","pubTimestamp":1786058703,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4581","BK4588","XBI","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657661971","title":"宜明昂科-B(01541)附屬宜明凱爾生物醫藥技術(上海)獲增資5000萬元","url":"https://stock-news.laohu8.com/highlight/detail?id=2657661971","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657661971?lang=zh_tw&edition=fundamental","pubTime":"2026-08-07 06:57","pubTimestamp":1786057046,"startTime":"0","endTime":"0","summary":"智通财经APP讯，宜明昂科-B 发布公告，于2026年8月6日，本公司、宜明凯尔生物医药技术(上海)有限公司、嘉兴张科领弋生科起航创业投资合伙企业、苏州新界创元企业管理合伙企业及王雪岩先生订立增资协议。根据增资协议，投资者同意以总对价人民币5000万元认缴合共人民币46.5万元经扩大注册资本，约占目标公司经扩大股权的15.83%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1477063.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["XBI","399441","BK4588","01541","BK4581","BK1161","BK4585","161726"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657619746","title":"宜明昂科-B(01541.HK)附屬宜明凱爾生物醫藥技術(上海)獲增資5000萬元","url":"https://stock-news.laohu8.com/highlight/detail?id=2657619746","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657619746?lang=zh_tw&edition=fundamental","pubTime":"2026-08-07 06:57","pubTimestamp":1786057046,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4581","BK4585","BK4588","XBI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1160721676","title":"醫療保健板塊市場動態綜述","url":"https://stock-news.laohu8.com/highlight/detail?id=1160721676","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1160721676?lang=zh_tw&edition=fundamental","pubTime":"2026-08-07 00:25","pubTimestamp":1786033543,"startTime":"0","endTime":"0","summary":"0739 ET - 伦敦上市制药商Hikma Pharmaceuticals上半年业绩表现强劲，但其对全年业绩的展望却显得颇为保守，并未随之上调，这令市场感到意外。这一积极表现主要得益于Hikma旗下品牌药部门的强劲增长，预计将受到投资者的欢迎。然而，即便上半年核心运营利润率大幅改善，Hikma仍坚持其2026年全年核心运营利润指引，即7.2亿至7.7亿美元，这一区间与市场普遍预期的7.31亿美元相比，并未显得更为乐观。受此消息影响，公司股价大涨10%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XBI","BK4585","BK4581","XLV","BK4588","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657070685","title":"生物科技IPO熱潮持續!心血管藥企Braveheart(BRVE.US)募資擴大至3.825億美元，發行價突破指引上限","url":"https://stock-news.laohu8.com/highlight/detail?id=2657070685","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657070685?lang=zh_tw&edition=fundamental","pubTime":"2026-08-06 16:28","pubTimestamp":1786004901,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["SYNB","REDS","BK4585","FRHC","BK4581","LNGR","BK4127","IEIH","XBI","BK4588","BRVE","KCE","AGNG","IBBJ","MEDX","GDOC","IPOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1137064261","title":"醫療板塊市場動態速覽","url":"https://stock-news.laohu8.com/highlight/detail?id=1137064261","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1137064261?lang=zh_tw&edition=fundamental","pubTime":"2026-08-06 16:26","pubTimestamp":1786004808,"startTime":"0","endTime":"0","summary":"1655 GMT - 礼来公司CEO David Ricks在CNBC上表示，该公司近期推出的每日一次GLP-1口服药Foundayo，尽管定价更低，但正在扩大市场而非蚕食现有市场。与此同时，减肥治疗的覆盖面持续扩大，进一步拓宽了潜在市场总规模。这些利好因素增强了礼来公司的信心，使其将营收预期从820亿至850亿美元上调至850亿至870亿美元。礼来股价目前上涨3%。市场对GLP-1减肥药的持续强劲需求推动第二季度营收跃升48%，达到229.7亿美元，超出预期的206.9亿美元。诺和诺德股价下跌4%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4581","XBI","BK4588","XLV","LABU","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657688495","title":"海關試點跨關區協同監管新模式","url":"https://stock-news.laohu8.com/highlight/detail?id=2657688495","media":"东北新闻网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657688495?lang=zh_tw&edition=fundamental","pubTime":"2026-08-06 15:12","pubTimestamp":1786000320,"startTime":"0","endTime":"0","summary":"为落实长三角一体化高质量发展重大战略部署，长三角区域海关协同推出进境动物源性生物材料联合监管试点，创新打造跨关区协同监管新模式，允许二级风险进境动物源性生物材料在同一集团、同等生物安全等级实验室间跨省市流转，一票通关、分段监管，由调出、调入海关分段实施闭环监管，从制度层面破除跨区域监管壁垒，充分释放生物医药创新要素流通活力。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2026-08-06/doc-inimkfvc3038063.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4588","XBI","BK4581","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657669688","title":"構建社保商保分層協同機制，破解創新藥支付困境——商業醫療保險與創新藥支付管理研討會在京召開","url":"https://stock-news.laohu8.com/highlight/detail?id=2657669688","media":"金融一线","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657669688?lang=zh_tw&edition=fundamental","pubTime":"2026-08-06 14:55","pubTimestamp":1785999300,"startTime":"0","endTime":"0","summary":"专题：新浪健康保险研究院2026年7月31日，由中央财经大学保险学院主办、新浪健康保险研究院协办的“商业医疗保险与创新药支付管理研讨会”在京举行。因此，在医保基金收支承压、商业保险资金池有限、天价药风险集中的现实约束下，造成创新药支付困境凸显。商保在创新药上市早期的支付补充价值。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/insurance/bxyy/2026-08-06/doc-inimkfvm3890828.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LABU","BK4581","BK1574","159992","MEDX","XLV","XBI","BK1161","BK4585","IBBQ","LNGR","06978","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657053195","title":"生物科技公司Braveheart在美國IPO中籌集3.825億美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2657053195","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657053195?lang=zh_tw&edition=fundamental","pubTime":"2026-08-06 10:47","pubTimestamp":1785984423,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IEIH","GDOC","LNGR","BK4585","TMSL","SMDX","ASCE","XBI","AGNG","SYNB","MEDX","IBBJ","BK4581","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657055503","title":"上海國投先導、恩華藥業等在上海成立創投基金","url":"https://stock-news.laohu8.com/highlight/detail?id=2657055503","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657055503?lang=zh_tw&edition=fundamental","pubTime":"2026-08-06 10:36","pubTimestamp":1785983777,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["XBI","BK4585","BK4581","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1198057342","title":"醫療保健板塊動態：市場快評","url":"https://stock-news.laohu8.com/highlight/detail?id=1198057342","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1198057342?lang=zh_tw&edition=fundamental","pubTime":"2026-08-06 00:29","pubTimestamp":1785947351,"startTime":"0","endTime":"0","summary":"最新医疗保健板块市场快讯，本报道仅在道琼斯通讯社于美东时间4:20、12:20及16:50独家发布。0429 ET - 伯恩斯坦分析师指出，诺和诺德第二季度财报表现超预期，并上调了业绩指引，但这对市场普遍预期的中值调整幅度微乎其微。Wegovy口服药的销售额低于市场预期，但公司强调，差异源于去库存行为。在哥本哈根，诺和诺德在财报公布后下跌4.4%。该股持平于1.06林吉特。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LABU","VOTE","JOYT","BK4581","GXDW","XBI","XLV","DECU","VGFPF","RGLO","PMDE","BK4585","FEBU","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1176091087","title":"醫療保健板塊快訊：市場動態一覽","url":"https://stock-news.laohu8.com/highlight/detail?id=1176091087","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1176091087?lang=zh_tw&edition=fundamental","pubTime":"2026-08-05 16:28","pubTimestamp":1785918487,"startTime":"0","endTime":"0","summary":"0736 GMT - 杰富瑞分析师在一份研究报告中指出，德国医疗保健集团费森尤斯正上调全年盈利指引，这得益于其Kabi制药部门增长驱动力的盈利能力提升。分析师表示，费森尤斯旗下Kabi业务在第二季度实现了17%的调整后营业利润率，其增长向量的利润率首次进入17%至19%的区间。此外，分析人士认为，德国医疗保健改革的获批，为集团旗下Helios医院部门消除了监管不确定性。费森尤斯股价上涨5.6%。在哥本哈根，诺和诺德在公布财报后下跌4.4%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VOTE","RGLO","XBI","LABU","FEBU","PMDE","JOYT","VGFPF","GXDW","BK4585","BK4588","BK4581","DECU","XLV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657359655","title":"高盛支持的生物科技公司Attovia在美國IPO中籌集2.89億美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2657359655","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657359655?lang=zh_tw&edition=fundamental","pubTime":"2026-08-05 09:08","pubTimestamp":1785892105,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4504","IBBJ","GDOC","LU0106831901.USD","ASCE","LU1868836757.USD","IE0004091025.USD","BK4533","LU2237438978.USD","BK4516","LU0868494708.USD","LU0345770308.USD","IE00B19Z3B42.SGD","LNGR","IEIH","LU2471134523.USD","LU1894683348.USD","IE00BFXG1179.USD","LU2471134952.CNY","XBI","MEDX","GSX","LU1668664300.SGD","LU0048573561.USD","BK4588","LU2471134879.HKD","IE0002270589.USD","LU2237443895.HKD","LU0942090050.USD","TMSL","LU1804176565.USD","IE0034235188.USD","LU1868836591.USD","LU2237443382.USD","LU2237443978.SGD","LU2750360641.GBP","LU1868837300.USD","BK4550","LU1894683264.USD","LU2237443465.HKD","SYNB","LU2237443549.SGD","SMDX","AGNG","IE0004086264.USD","BK4585","LU0742534661.SGD","LU2265009873.SGD","LU2237443622.USD","LU1791807156.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1151299937","title":"醫療保健板塊動態：市場快評","url":"https://stock-news.laohu8.com/highlight/detail?id=1151299937","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1151299937?lang=zh_tw&edition=fundamental","pubTime":"2026-08-05 04:57","pubTimestamp":1785877040,"startTime":"0","endTime":"0","summary":"1038 ET - 摩根大通分析师指出，葛兰素史克新近推出的药物，将是降低这家英国药企明年前景风险的关键。葛兰素史克近期推出了血癌药物Blenrep和哮喘治疗药物Exdensur，而通过收购Nuvalent获得的肺癌药物Jideytro，也在上月获得美国批准。0123 ET - 摩根大通分析师在一份研究报告中表示，费森尤斯医疗第二季度业绩超出市场预期，但该公司重申全年业绩指引，暗示未来几个季度盈利可能收缩。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XLV","LABU","BK4581","XBI","BK4585","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1122423549","title":"醫療保健板塊動態：市場快評","url":"https://stock-news.laohu8.com/highlight/detail?id=1122423549","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1122423549?lang=zh_tw&edition=fundamental","pubTime":"2026-08-05 00:26","pubTimestamp":1785860812,"startTime":"0","endTime":"0","summary":"**GSK新品上市，能否化解明年风险？GSK近期推出了血癌药物Blenrep和哮喘治疗药Exdensur，而通过收购Nuvalent获得的肺癌药物Jideytro，上月也已获得美国批准。0123 ET - 摩根大通分析师在研报中表示，费森尤斯医疗第二季度业绩超出市场预期，但公司重申全年指引，暗示未来几个季度盈利可能收缩。这家德国透析专科公司公布的季度调整后营业利润为5.69亿欧元，高于市场普遍预期的5.14亿欧元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4588","LABU","XBI","XLV","BK4581"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656255361","title":"睿唯盛高管在電話會議上表示，受人工智能相關訂單數量增長的推動，公司正迎來生物科技客户需求改善。","url":"https://stock-news.laohu8.com/highlight/detail?id=2656255361","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656255361?lang=zh_tw&edition=fundamental","pubTime":"2026-08-04 19:41","pubTimestamp":1785843719,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["WPAI","PSQ","NEWZ","PBOT","AIQU","QQQM","AGNG","QSWN","NJUL","AIFD","NAPR","QDEC","KOMP","MVPS","NOCT","QTOC","IEIH","SYNB","GDOC","AIBU","MEDX","SQQQ","CPNQ","DQJN","IBBJ","TARK","QQQX","QQQ","XBI","NBDS","LCLG","CHAT","CWC","QLD","QID","QMAR","TQQY","AQGX","GK","QQA","TECY","AGIX","OGIG","TQQQ","FWD","MFIG","VUSE","NJAN","LNGR","ARTY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656300500","title":"「創新+出海」驅動，A股生物醫藥公司盈利能力提升","url":"https://stock-news.laohu8.com/highlight/detail?id=2656300500","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656300500?lang=zh_tw&edition=fundamental","pubTime":"2026-08-04 06:29","pubTimestamp":1785796151,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["XBI","BK4585","BK4581","PSET","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1198971052","title":"醫療健康板塊快訊：市場動態一覽","url":"https://stock-news.laohu8.com/highlight/detail?id=1198971052","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1198971052?lang=zh_tw&edition=fundamental","pubTime":"2026-08-04 04:56","pubTimestamp":1785790601,"startTime":"0","endTime":"0","summary":"分析师指出，尽管投资者此前主要担忧仿制药会蚕食其畅销抗癌药Somatuline的销售额，但瑞典Camurus公司的实验性药物CAM2029才是更长期的威胁。一项针对CAM2029治疗神经内分泌肿瘤的晚期研究结果将于2026年底或2027年初公布，分析人士认为，其结果很可能会优于Somatuline。考虑到Somatuline贡献了益普生约30%的销售额且利润极高，这无疑会给公司盈利带来巨大压力。Jefferies因此将益普生的评级从“持有”下调至“跑输大盘”。受此影响，其股价下跌8.2%，报153.50欧元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XLV","XBI","BK4585","BK4581","LABU","BK4588"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":10,"totalSize":200,"code":"91000000","status":"200"}]}}